Acute myelogenous leukaemia following etanercept therapy [1]

Rheumatology

Volumn 42, Issue 7, 2003, Pages 900-901

  Bakland, G ^a   Nossent, Hans ^a,b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYTARABINE; DAUNORUBICIN; ETANERCEPT; GONADORELIN DERIVATIVE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; STEROID; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANKYLOSING SPONDYLITIS; ARTHRALGIA; ARTHRITIS; CANCER RISK; CASE REPORT; CHROMOSOME ANALYSIS; ENDOMETRIOSIS; ERYTHEMA NODOSUM; FATIGUE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; LETTER; LEUKOPENIA; MORNING STIFFNESS; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SPINE DISEASE; UVEITIS;

ADULT; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; IMMUNOGLOBULIN G; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKOPENIA; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING;

EID: 0043072905     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keg128     Document Type: Letter

References (10)

1. Moreland LW, Schiff MH, Baumgartner SW et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
2. Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of Etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
3. Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum 2001;44:1149-54.
4. Iyer S, Yamauchi P, Lowe NJ. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol 2002;146:118-21.
5. Phillips K, Husni ME, Karlson EW, Coblyn JS. Experience with Etanercept in an academic medical center: are infection rates increased? Arthritis Rheum 2002;47:17-21.
6. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with Infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
7. Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Matteson EL. Fatal sepsis in a patient with rheumatoid arthritis treated with Etanercept. Mayo Clin Proc 2001;76:653-6.
8. Fleischmann R, Iqbal I, Nandeshwar P, Quiceno A. Safety and efficacy of disease modifying anti-rheumatic agents: focus on the benefits and risks of Etanercept. Drug Saf 2002;25:173-97.
9. Weiss HA, Darby SC, Fearn T, Doll R. Leukaemia mortality after X-ray treatment for ankylosing spondylitis. Radiat Res 1995; 142:1-11.
10. An WY, Hawkins BR, Cheng N, Lie AK, Liang R, Kwong YL. Risk of haematological malignancies in HLA-B27 carriers. Br J Haematol 2001;115:320-2.